$ALHC

Kent Mark D. purchased $198K of ALHC

Kent Mark D. (President - MSO) purchased 14,848 shares of Alignment Healthcare, Inc. (ALHC) at $13.31 ($0.20M total) on 2026-06-02.

Original reporting
SEC EDGAR · Kent Mark D.
Published Jun 2, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Bullish
medium confidence
Mentioned
$ALHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBullishLow
01

Why it matters

The disclosure may slightly improve near-term sentiment and can be used as a supportive input for positioning, but it does not change the company’s fundamentals on its own.

02

Market read

A same-day insider open-market buy of ~14,848 shares at ~$13.31/share is a modest positive signal for ALHC sentiment.

03

What to watch

Check whether the officer has a history of buys/sells and whether there are concurrent corporate events (financing, guidance, contracts) not captured in this Form 4.

Relevance 7/10Novelty 6/10Timing: Filed same day as the open-market purchase (2026-06-02).

Background

This is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc., showing an officer/direct purchase.

Company-level read

Ticker impact

$ALHCBullishMedium confidence
Context

Alignment Healthcare officer Kent Mark purchased $197.6K of ALHC shares in an open-market transaction on 2026-06-02.

Expected impact

Likely limited/short-lived impact; any reaction should be small unless accompanied by other news.

Evidence & confidence

The filing provides a concrete buy datapoint (size and date) but no new operational, financial, or deal information; also no 10b5-1 plan is cited.

Market effects

Minimal; this is company-specific insider activity with no sector-wide policy or competitive signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by personal liquidity/tax planning; without broader fundamentals, follow-through may not materialize.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the insider transaction filing (ALHC).

  • Kent Mark

    President - MSO who reported an open-market purchase of ALHC shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$ALHCMed

Alignment Health seeks to have former exec's whistleblower suit tossed

Alignment Healthcare and executives filed to dismiss a whistleblower suit by former exec Hakan Kardes, who alleges earnings were artificially boosted for higher bonuses. The company claims Kardes resigned voluntarily and his claims are false. Kardes says he was forced out after reporting accounting irregularities, affecting EBITDA and executive bonuses. Shares dropped initially but rebounded.

$ALHCMed

Alignment Healthcare (ALHC) Stock Drops 16.7% After Whistleblower Accounting Allegations Trigger Securities Investigation

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations at Alignment Healthcare, Inc. (NASDAQ: ALHC) after a whistleblower complaint alleging accounting irregularities that allegedly inflated previously reported and projected results. The complaint cites operating expenses allegedly misclassified as capital expenditures, affecting Adjusted EBITDA. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.